Abstract-This study was designed to determine the extent , to which isosorbide 5-mononitrate (5-ISMN) contributes to the hemodynamic effect of isosorbide dinitrate (ISDN) in conscious dogs. Test drugs (ISDN or 5-ISMN) were given orally. Either ISDN or 5-ISMN produced a decrease in blood pressure dose dependently, the decrease in pulse pressure being specific; the pattern of blood pressure change induced by ISDN or 5-ISMN was different from that induced by nifedipine or prazosin. The effect of ISDN (2 mg/kg) was almost equivalent to that of 5-ISMN (4 mg/kg) and the effect of ISDN (4 mg/kg) to that of 5-ISMN (8 mg/kg). After administration of ISDN, both ISDN and 5-ISMN appeared in the plasma, and the effect of ISDN well-correlated with the increase in the plasma concentration of 5-ISMN. Contribution of 5-ISMN to the effect of ISDN was estimated to be about 30% from the value of the plasma concentration of 5-ISMN at 3 to 4 hr after administration, when the maximal response to ISDN occurred . Based on the data of the area under the plasma concentration curve of 5-ISMN (from 0 to 10 hr after administration), the fraction of biotransformation to 5-ISMN from ISDN was calculated to be 73.6 to 76.6% (based on moles). Because the ability of 5-ISMN to decrease pulse pressure was about 1 /2 (or 41% based on moles) of that of ISDN, the contribution of 5-ISMN to the effect of ISDN was estimated to be about 30% in total, the value being similar with that estimated at 3 to 4 hr after administration.
Isosorbide dinitrate (ISDN) is an organic nitrate widely used for treatment of angina pectoris (1) (2) (3) . ISDN is biotransformed ex tensively by the enzyme glutathione organic nitrate reductase to isosorbide-2-mononitrate (2-ISMN) and isosorbide-5-mononitrate (5 ISMN) (4-6), the latter being a major me tabolite of ISDN that is pharmacologically active in animals (7, 8) and man (9). The bioavailability of ISDN, therefore, is as low as 3% (10). In contrast to ISDN, 5-ISMN can be almost completely absorbed from the gastrointestinal tract and remains almost unchanged in the body, and therefore bio availability of 5-ISMN is near 100% (11). For this reason, 5-ISMN has been expected to be used for treatment of patients with angina pectoris (12) (13) (14) .
Although the bioavailability of ISDN is low, the duration of its action is relatively long. Recently, we have suggested that the relatively long action of ISDN could be due to the relatively high and long lasting blood levels of 5-ISMN following oral adminis tration of ISDN (15) .
The purpose of the present study was to determine the extent, to which the phar macological effect of orally administered ISDN depends on the effect of 5-ISMN that can be found in the plasma after adminis tration of ISDN. For this purpose, we measured the blood levels of both ISDN and 5-ISMN after oral administration of ISDN or 5-ISMN and examined their pharmaco logical actions. In addition, the actions of ISDN and 5-ISMN were compared with those of prazosin and nifedipine.
Materials and Methods
Experimental protocol: Cross-over experi ments were performed in 12 conscious mongrel dogs of either sex, weighing 7-12 kg. Dogs were divided into two groups and 2 subgroups each; and to each dog, two kinds of drugs were administered orally according to the following protocol.
I. Low dose group I(a) ( I(a), ISDN (2 mg/kg) was initially given (the first administration), and then after a week, 5-ISMN (4 mg/kg) was given (the second administration).
In both cases of drug administration, plasma levels of ISDN and 5-ISMN and blood pressure were measured from the time of administration until 10 hr after administration.
(When 5 ISMN was given, the plasma level of only 5-ISMN was measured, because ISDN does not appear in the plasma in this case). In subgroup I(b), 5-ISMN (4 mg/kg) was initially given (the first administration), and after a week, ISDN (2 mg/kg) was given (the second administration).
In the same way, 4 mg/kg of ISDN and 8 mg/kg of 5 ISMN were given in subgroups 11(a) and 11(b). In each case of drug administration, both the plasma level of drugs and blood pressure were measured. Thus, the data with ISDN (2 mg/kg, 6 dogs) and those with 5 ISMN (4 mg/kg, 6 dogs) were obtained from the low dose group, and the data with ISDN (4 mg/kg, 6 dogs) and those with 5-ISMN (8 mg/kg, 6 dogs) were obtained from the high dose group.
In addition, 24 conscious mongrel dogs were used for comparative hemodynamic experiments with ISDN, 5-ISMN, prazosin and nifedipine, in which experiments were performed in a noncross-over manner. In this series of studies, only hemodynamic data were obtained.
Drug administration: Drugs were admin istered orally in both cross-over and non cross-over experiments. Each dog was fasted for 24 hr before drug administration and received test drugs with some water at the time of administration. Measurements of hemodynamics: Under anesthesia with sodium pentobarbital (25 mg/kg), an arterial catheter was implanted aseptically according to our method (15, 16) described as follows. A 1.5-2.0 cm incision of the skin at the part of the right cervix was made. The right carotid artery was then exposed and carefully dissected free. An arterial catheter, which was filled with sterile physiologic saline containing sodium heparin (1000 units/ml), was introduced retrogradely through the right carotid artery. The other end of the arterial catheter was exteriorized through the skin at the neck. Experiments were performed 3-5 days after the catheter implantation.
The chronically implanted catheter was connected to a pressure trans ducer (Nihon Kohden RP-5), and the systolic and diastolic blood pressure was measured. Heart rate was measured directly with a cardiotachometer (Nihon Kohden RT-5) trig gered by the pulse of arterial blood pressure. The pulse pressure (systolic pressure diastolic pressure) was also determined. During measurements of blood pressure, the unrestrained experimental animal was gently sitting on the floor of a sound-proof room by the side of an experimenter.
Measurements of plasma concentrations of ISDN and 5-ISMN: Blood samples were withdrawn before dosing and 1, 2, 3, 4, 6, 8 and 10 hr after dosing. The samples were centrifuged immediately after withdrawal, and the separated plasma was stored at -20°C until analysis was performed . Plasma concentrations of ISDN and 5-ISMN were measured by a gas chromatograph according to Kato's method (17).
Extraction of ISDN: Plasma was extracted with n-hexane, which was re-extracted with acetonitrile. The acetonitrile layer was trans ferred to another vial and then evaporated under nitrogen to near dryness at room temperature.
The residue was dissolved in ethyl acetate after addition of an internal standard (isomannide dinitrate), and a portion of the ethyl acetic solution was injected into a gas chromatograph (Hewlett-Packard, 5710A).
Extraction of 5-ISMN: Plasma was ex tracted with ethyl acetate, and the organic phase was transferred to another vial. After evaporation of the pooled ethyl acetate to near dryness, the residue was dissolved in an appropriate volume of ethyl acetate. A portion of the ethyl acetic solution after addition of an internal standard (2,4 dinitrochlorobenzene) was injected into a gas chromatograph (Shimadzu, 4BM). Fraction of biotransformation to 5-ISMN: The area under the plasma concentration curve (AUC) of 5-ISMN (from 0 to 10 hr after administration) was measured when ISDN or 5-ISMN was administered.
From the AUC and the amount of drugs given orally, the fraction of biotransformation to 5 ISMN from ISDN was calculated. The AUC/mg/kg of 5-ISMN when 4 mg/kg of 5-ISMN was administered was defined as 100%. In the case of ISDN administered, the fraction of biotransformation to 5-ISMN was calculated from the AUC/mg/kg to that of administered 5-ISMN (4 mg/kg).
Reagents:
The source of the test com pounds were as follows: isosorbide dinitrate (ISDN) from Toho Kasei Kogyo Co., Ltd., Japan;
isosorbide-5-mononitrate (5-ISMN) from Toa Eiyo, Ltd., Japan; prazosin from Orion Corporation, Ltd., Fermion, Finland; and nifedipine from Toho Kasei Kogyo Co., Ltd., Japan. and those immediately before the second administration (5-ISMN, 4 mg/ kg) were 163±10 and 73±14 mmHg, and 127±9 beats/min, respectively. In group I(b), systolic and diastolic blood pressure, and heart rate before the first administration (5 ISMN, 4 mg/kg) were 143±8 and 76±4 mmHg, and 123±16 beats/min, respec tively, and those immediately before the second administration (ISDN, 2 mg/kg) were 138±2 and 69±2 mmHg, and 128±19 beats/min, respectively. Thus there was no marked difference in blood pressure and heart rate between the first and the second administrations.
The hemodynamic effect of ISDN (2 mg/ kg) and that of 5-ISMN (4 mg/kg) are shown in Fig. 1 (left panel) . Oral adminis tration of either ISDN (2 mg/kg) or 5-ISMN (4 mg/kg) caused a significant decrease in systolic blood pressure, reaching its maximal reduction of 18 mmHg or 24 mmHg, respec tively, 3 hr after administration and remaining decreased through 10 hr. There were not remarkable changes in diastolic blood pres sure after administration of each of the agents.
The mean blood pressure also decreased slightly in response to each of the agents, but the degree of changes in mean blood pressure was less than that in systolic blood pressure. Heart rate increased transi ently after the administration of each of ISDN and 5-ISMN.
1-1-2. High dose group: In group of 11(a), systolic and diastolic blood pressure, and heart rate immediately before the first admin istration (ISDN, 4 mg/kg) were 162±6.0 and 75±5 mmHg, and 104±15 beats/min, respectively; and those immediately before the second administration (5-ISMN, 8 mg/ kg) were 149±2 and 64±3 mmHg, and 104±12 beats/min, respectively. In group 11(b), systolic and diastolic blood pressure, and heart rate immediately before the first administration (5-ISMN, 8 mg/kg) were 164±21 and 72±10 mmHg, and 142±10 beats/min, respectively; and those im mediately before the second administration (ISDN, 4 mg/kg) were 163±18 and 73±14 mmHg, and 135±7 beats/min, respectively. Thus there was no marked difference in blood pressure and heart rate between the first and the second administrations.
The hemodynamic effect of ISDN (4 mg/ kg) and that of 5-ISMN (8 mg/kg) are shown in Fig. 1 (right panel) . An administration of ISDN (4 mg/kg) or 5-ISMN (8 mg/kg) decreased systolic blood pressure con siderably, reaching its maximal reduction of 33 mmHg or 39 mmHg, respectively, 2 hr after administration.
The response of systolic blood pressure to ISDN and that to 5-ISMN generally resembled each other. Diastolic blood pressure did not change, while mean blood pressure significantly decreased after administration of each of the agents. Heart rate increased slightly after the administration of these agents. 1-2. Plasma concentrations of ISDN and 5 ISMN in relation to the decrease in pulse pressure Administration of either ISDN or 5-ISMN produced a remarkable decrease in systolic blood pressure rather than in diastolic blood pressure; and therefore, pulse pressure was reduced by these agents. Figure 2 shown in Fig. 2 Fig. 2 (right panel) . Either ISDN (4 mg/kg) or 5-ISMN (8 mg/kg) decreased pulse pressure significantly, reaching its maximal reduction of 40% or 43%, respectively, 2 hr after administration.
Thereafter, the decrease in pulse pressure gradually declined to 16% 10 hr after dosing of ISDN. After oral admin istration of ISDN (4 mg/kg), both ISDN and 5-ISMN were detected in the plasma. The plasma concentration of ISDN increased and reached maximum within 1 hr after administration and then declined rapidly, being undetectable in the plasma 6 hr after administration.
However, significant decrease (26%) in pulse pressure was still observed 6 hr after the administration, when the plasma 5-ISMN was still high (620 ng/ml). Oral administration of 5-ISMN (8 mg/kg) in creased the plasma levels of 5-ISMN maxi mally (4099 ng/ml) after 2 hr of dosing, the 5-ISMN concentration declining gradually to 578 ng/ml 8 hr after administration. There was a good correlation between the decrease in pulse pressure and the increase in plasma level of 5-ISMN in both cases of ISDN and
Thus the results were essentially the same as those in the low dose group, although the responses were greater in the high dose group.
1-2-3. ISDN vs. 5-ISMN administration: The relationship between the plasma con centration of 5-ISMN and percent decrease in pulse pressure in dogs receiving ISDN (4 mg/kg) (Fig. 3, right panel) or 5-ISMN (4 mg/kg) (Fig. 3, left panel) is shown in Fig. 3 . There was a good correlation between them after administration of ISDN (r=0.935, P<0.05) or 5-ISMN (r=0.893, P<0.05).
Noncross-over experiments
The hemodynamic effects of ISDN, 5 ISMN, prazosin and nifedipine were com paratively studied in this series of experiments. The systolic and diastolic blood pressure, pulse pressure and heart rate before adminis tration of drugs were 155±3 and 77±4 mmHg, 77±3 mmHg and 116±5 beats/min, respectively. Figure 4 illustrates the maximal percent changes of blood pressure and heart rate after administration of agents. Because ISDN and 5-ISMN caused a significant decrease in systolic blood pressure without a remarkable change in diastolic blood pressure, the pulse pressure decreased markedly. On the other hand, nifedipine markedly decreased both diastolic and systolic blood pressure, the decrease in the former being greater than that in the latter. Therefore, the pulse pressure increased.
Prazosin produced a significant Fig. 3 . Linear regression analysis of the relation between plasma concentration of 5-ISMN and percent decrease of pulse pressure after oral administration of 5-ISMN (4 mg/kg) or ISDN (4 mg/kg). These results were obtained from the experiments shown in Fig. 2 . Each point represents a mean+S.E. 
Discussion
There is a view that the long lasting effect of ISDN could be due to the effect of 5 ISMN, being a major metabolite of ISDN (18). The present study was designed to examine this view and determine the extent to which the effect of ISDN depends on the effect of 5-ISMN.
First, the pharmacological effects of ISDN and 5-ISMN were studied. Figure 1 clearly shows that ISDN decreases blood pressure dose-dependently, and this effect of ISDN is similar with that of 5-ISMN. It is of interest to note that the effect of ISDN (2 mg/kg) is very similar with that of 5-ISMN (4 mg/kg), and the effect of ISDN (4 mg/kg) is also very similar with that of 5-ISMN (8 mg/kg), indicating that the effect of 5-ISMN is about 1 /2 (or 41 % based on moles) of the effect of ISDN.
Next, the relationship between the effect of ISDN and the plasma concentrations of ISDN and its metabolite, 5-ISMN, was studied. As an indicator of the effect of ISDN, the pulse pressure was chosen, because the pulse pressure has been shown to be a sensitive indicator of the hemodynamic response to ISDN (15, 19) . In fact, the pulse pressure decreased markedly in response to either ISDN or 5-ISMN (Fig. 4) . In addition, the pattern of the effect of ISDN or 5-ISMN on blood pressure was different from that of nifedipine and also different from that of prazosin (Fig. 4) . Therefore, the pulse pressure can be used for evaluation of the effect of ISDN and 5-ISMN. One of the most characteristic findings of the results shown in Fig. 2 is that the time course-pattern of the effect of ISDN did not parallel that of the plasma concentration of ISDN, but paralleled that of its metabolite, 5 ISMN. The administration of ISDN (2 mg/ kg) produced a decrease in pulse pressure, and this effect still remained even when the plasma concentration of ISDN became zero (4 hr after administration), although the plasma concentration of 5-ISMN was as high as 467 ng/ml. As was described earlier, the administration of 5-ISMN (4 mg/kg) also produced a decrease in pulse pressure, which was similar in degree with that pro duced by ISDN (2 mg/kg). When the percent ratio of plasma concentration of 5-ISMN at a given time after administration of ISDN to that after administration of 5-ISMN is defined as the 5-ISMN ratio, the values of the 5 ISMN ratio at 1, 2, 3, 4 and 6 hr after admin istration of drugs are 21%, 19%, 24%, 33% and 44%, respectively, in the low dose group. In the high dose group, the values of the 5-ISMN ratio at 1, 2, 3, 4 and 6 hr after administration of drugs are 18%, 23%, 32%, 41% and 52%, respectively.
These results suggest that 5-ISMN contributes to the effect of ISDN by 20-50% depending on the elapsed time after administration of ISDN. Other metabolites of ISDN, such as 2 ISMN, and ISDN itself should also con tribute to the effect of ISDN given orally, although the extent to which they contribute to the effect of ISDN has not yet been determined.
However, 2-ISMN is me tabolized at a faster rate than 5-ISMN; this can be ascribed to the rapid denitration of its exposed 2-exo position rather than that of the sterically shielded 5-endo position (6 8). These facts indicate that the relatively prolonged action of ISDN is largely ascribable to 5-ISMN rather than 2-ISMN.
There is another way to calculate the extent to which 5-ISMN contributes to the effect of ISDN. According to the pharmacokinetic data, the AUC/mg/kg of 5-ISMN from 0 to 10 hr after the administration of ISDN (2 and 4 mg/kg) was 73.6 to 76.6% compared with that after the administration of 5-ISMN (4 mg/kg) ( Table 1 ), indicating that 73.6 to 76.6% of ISDN (based on moles) is trans formed to 5-ISMN in the body. This finding was in accord with data from the literature (20, 21). In addition, the effect of 2 mg/kg of ISDN was nearly equivalent to that of 4 mg/ kg of 5-ISMN, suggesting that the effect of 5-ISMN is about 41% of that of ISDN based on moles. Therefore, the contribution of 5 ISMN to the effect of ISDN is 30 to 31% in total. This value accords well with the value of the 5-ISMN ratio obtained 3 to 4 hr after administration of ISDN.
From the foregoing results, it is concluded that ISDN is biotransformed to 5-ISMN, which is active in decreasing pulse pressure, and that the degree of contribution of 5 ISMN to the effect of ISDN given orally is about 30% at the time of 3 to 4 hr after administration of ISDN, when the effect of orally given ISDN becomes nearly maximal.
